HC Wainwright Reiterates “Buy” Rating for Tango Therapeutics (NASDAQ:TNGX)

Tango Therapeutics (NASDAQ:TNGX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $13.00 target price on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

Tango Therapeutics Stock Up 2.6 %

Shares of Tango Therapeutics stock opened at $1.38 on Monday. The stock has a market cap of $148.65 million, a price-to-earnings ratio of -1.17 and a beta of 1.03. Tango Therapeutics has a twelve month low of $1.11 and a twelve month high of $12.02. The company’s fifty day moving average is $1.88 and its 200 day moving average is $3.39.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. As a group, equities analysts anticipate that Tango Therapeutics will post -1.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 24,268 shares of company stock worth $72,561. 6.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Woodline Partners LP bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at about $1,219,000. Squarepoint Ops LLC bought a new position in shares of Tango Therapeutics during the 4th quarter worth approximately $40,000. Two Sigma Advisers LP acquired a new stake in shares of Tango Therapeutics during the 4th quarter worth approximately $81,000. Stonebrook Private Inc. bought a new stake in shares of Tango Therapeutics in the 4th quarter valued at $34,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Tango Therapeutics during the 4th quarter valued at $38,000. 78.99% of the stock is owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.